2026 Global: Congenital Hyperinsulinism Market -Competitive Review (2032) report
Description
The 2026 Global: Congenital Hyperinsulinism Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for congenital hyperinsulinism market by geography and historical trend. The scope of the report extends to sizing of the congenital hyperinsulinism market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zealand Pharma is developing dasiglucagon, a glucagon analog designed for continuous subcutaneous infusion to raise blood glucose in infants and children with congenital hyperinsulinism (CHI), and has reported positive trial data supporting its potential as a novel CHI therapy. Hanmi Pharmaceutical is advancing efpegerglucagon (HM15136), a once‑weekly glucagon analog in Phase 2 studies that the company has presented at pediatric endocrinology meetings and positioned as a long‑acting option to reduce hypoglycemia burden in CHI patients. Rezolute is developing ersodetug (RZ358), a fully human monoclonal antibody intended to prevent severe hypoglycemia across genetic forms of hyperinsulinism and has progressed to pivotal Phase 3 programs for congenital hyperinsulinism. Crinetics Pharmaceuticals is pursuing CRN04777, an oral nonpeptide SST5 agonist designed to reduce insulin secretion, which entered first‑in‑human studies as an oral therapeutic candidate that could treat multiple CHI genotypes. Xeris Biopharma (Xeris/Xeris Biopharma Holdings) leverages stabilized liquid glucagon formulations such as Gvoke that improve acute hypoglycemia management and have been examined in pediatric settings relevant to CHI supportive care. Eiger BioPharmaceuticals and related specialty biotechs have appeared in market reports as participants in CHI research and pipeline activity, contributing niche programs and collaborations aimed at rare endocrine disorders. AmideBio and other small biotech firms are listed among market players developing investigational agents or supportive technologies for CHI, often focusing on formulation, delivery, or adjunctive therapies to improve outpatient management for infants and children. Hanmi, Zealand and several specialty companies have also engaged with patient advocacy groups and clinical communities to advance genetic testing and trial recruitment, recognizing that earlier diagnosis and genotype‑directed approaches are central to improving outcomes in CHI. Larger pharmaceutical companies such as Eli Lilly, Novo Nordisk and Fresenius Kabi appear in broader market summaries and competitive landscapes, typically through capabilities in peptide therapeutics, glucagon products, or hospital supply chains that could support CHI treatment distribution and scale if their CHI‑directed programs expand. Amylyx (now a clinical‑stage firm with programs including avexitide) and other mid‑sized rare‑disease companies have pursued repurposing or novel mechanisms (e.g., peptide antagonists, monoclonal antibodies, receptor modulators) to offer oral or injectable alternatives to current standards like diazoxide and off‑label somatostatin analogs, reflecting a market trend toward disease‑modifying and genotype‑agnostic therapies. Market analyses project a modestly growing CHI market driven by novel pipeline approvals, improved newborn genetic screening, and greater adoption of targeted biologics and long‑acting glucagon analogs from the companies listed above.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for congenital hyperinsulinism market by geography and historical trend. The scope of the report extends to sizing of the congenital hyperinsulinism market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zealand Pharma is developing dasiglucagon, a glucagon analog designed for continuous subcutaneous infusion to raise blood glucose in infants and children with congenital hyperinsulinism (CHI), and has reported positive trial data supporting its potential as a novel CHI therapy. Hanmi Pharmaceutical is advancing efpegerglucagon (HM15136), a once‑weekly glucagon analog in Phase 2 studies that the company has presented at pediatric endocrinology meetings and positioned as a long‑acting option to reduce hypoglycemia burden in CHI patients. Rezolute is developing ersodetug (RZ358), a fully human monoclonal antibody intended to prevent severe hypoglycemia across genetic forms of hyperinsulinism and has progressed to pivotal Phase 3 programs for congenital hyperinsulinism. Crinetics Pharmaceuticals is pursuing CRN04777, an oral nonpeptide SST5 agonist designed to reduce insulin secretion, which entered first‑in‑human studies as an oral therapeutic candidate that could treat multiple CHI genotypes. Xeris Biopharma (Xeris/Xeris Biopharma Holdings) leverages stabilized liquid glucagon formulations such as Gvoke that improve acute hypoglycemia management and have been examined in pediatric settings relevant to CHI supportive care. Eiger BioPharmaceuticals and related specialty biotechs have appeared in market reports as participants in CHI research and pipeline activity, contributing niche programs and collaborations aimed at rare endocrine disorders. AmideBio and other small biotech firms are listed among market players developing investigational agents or supportive technologies for CHI, often focusing on formulation, delivery, or adjunctive therapies to improve outpatient management for infants and children. Hanmi, Zealand and several specialty companies have also engaged with patient advocacy groups and clinical communities to advance genetic testing and trial recruitment, recognizing that earlier diagnosis and genotype‑directed approaches are central to improving outcomes in CHI. Larger pharmaceutical companies such as Eli Lilly, Novo Nordisk and Fresenius Kabi appear in broader market summaries and competitive landscapes, typically through capabilities in peptide therapeutics, glucagon products, or hospital supply chains that could support CHI treatment distribution and scale if their CHI‑directed programs expand. Amylyx (now a clinical‑stage firm with programs including avexitide) and other mid‑sized rare‑disease companies have pursued repurposing or novel mechanisms (e.g., peptide antagonists, monoclonal antibodies, receptor modulators) to offer oral or injectable alternatives to current standards like diazoxide and off‑label somatostatin analogs, reflecting a market trend toward disease‑modifying and genotype‑agnostic therapies. Market analyses project a modestly growing CHI market driven by novel pipeline approvals, improved newborn genetic screening, and greater adoption of targeted biologics and long‑acting glucagon analogs from the companies listed above.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
